ATR and glioblastoma: Considering the lack of benefit from ICI therapies within glioblastoma due to low immune infiltrates [47], the stimulation of innate immune response and antigen presentation through ATR inhibition is a potential therapeutic strategy that could synergise with current anti-PD1/PD-L1 inhibitors.